Apply for funding to support emerging or established research partnerships between businesses and academic partners (lead must be UK-based).
Co-developed programmes should focus on the safety and toxicity of advanced therapies, developing tools and resources to assess and mitigate safety risks. The research will integrate discovery and translational science, aiming to propel future advanced therapies into clinics.
Multiple academic and business partners can participate, with MRC funding academic costs of £2 million to £4 million Full Economic Cost (FEC) for up to five years. Equal contribution is expected by the business partner(s).
International applicants
You can include international applicants as programme co-leads (international), where they will make a major intellectual contribution to the design or conduct of the programme. The contribution and added value to the research collaboration should be clearly explained and justified in the application.
Equality, diversity and inclusion
We are committed to achieving equality of opportunity for all funding applicants. We encourage applications from a diverse range of researchers.
We support people to work in a way that suits their personal circumstances. This includes:
To apply for this funding opportunity, you must have completed the mandatory expression of interest stage (that closed on 6 November 2024) and have been invited to this full stage of the funding opportunity. See ‘how to apply’ for more information.
Applications must be co-developed and led by an academic lead (project lead in the UK Research and Innovation (UKRI) Funding Service) and a lead business project partner (the primary business partner in the partnership).
Who is eligible to apply
Research organisations can act as the academic lead if they are eligible to receive UKRI funding.
Businesses can act as the lead project partner if they are:
Businesses may be a contributor to other applications as a project partner. Other businesses can collaborate in the partnership as project partners, but the majority of the matched contribution is expected from the lead business partner.
Before applying for funding, check the Eligibility of your organisation.
UKRI has introduced new role types for funding opportunities being run on the new Funding Service.
For full details, visit Eligibility as an individual.
A research organisation may lead or partner on more than one application and applications may comprise more than one research organisation.
For applicants who do not have a contract of employment for the duration of the proposed programme, by submitting an application the research organisation is confirming, if it is successful:
The application must also be codeveloped by a minimum of one ‘business’ lead/ partner. Businesses can act as the lead project partner if they are:
Businesses may be a contributor to other applications as a project partner. Other businesses can collaborate in the partnership as project partners, but the majority of the matched contribution is expected from the lead business partner.
Who is not eligible to apply
You are not eligible to apply for this funding opportunity as a lead if you are based at an international research organisation. This does not include MRC Unit The Gambia or MRC/UVRI Uganda Research Unit at the London School of Hygiene and Tropical Medicine that are eligible to apply as project lead. Before applying for funding, check the Eligibility of your organisation.
Eligible Countries:
Sponsor Institute/Organizations: Medical Research Council (MRC)
Address: Polaris House, North Star Avenue, Swindon, SN2 1FL
Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.
Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.
Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.
Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.
Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.
Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.
Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.
Feb 12, 2025
$4,867,399
Affiliation: Medical Research Council (MRC)
Address: Polaris House, North Star Avenue, Swindon, SN2 1FL
Website URL: https://www.ukri.org/opportunity/prosperity-partnerships-advanced-therapies-safety-and-toxicity/
Disclaimer:It is mandatory that all applicants carry workplace liability insurance, e.g., https://www.protrip-world-liability.com (Erasmus students use this package and typically costs around 5 € per month - please check) in addition to health insurance when you join any of the onsite Trialect partnered fellowships.